Quoin pharmaceuticals announces european medicines agency (ema) grants orphan drug designation for qrx003 for the treatment of netherton syndrome

Company continues to advance qrx003 in late-stage clinical trials in netherton syndrome patients regulatory milestone provides 10 years of market exclusivity in europe upon approval ashburn, va., may 20, 2025 (globe newswire) -- quoin pharmaceuticals ltd.
QNRX Ratings Summary
QNRX Quant Ranking